Adding insulin glargine vs. NPH insulin to metformin results in a more efficient postprandial beta-cell protection in individuals with type 2 diabetes

T Forst, M Larbig, C Hohberg, S Forst, S Diessel, M Borchert, W Roth, A Pfützner, T Forst, M Larbig, C Hohberg, S Forst, S Diessel, M Borchert, W Roth, A Pfützner

Abstract

Aim: Postprandial release of intact proinsulin (IP) is an independent marker for beta-cell dysfunction in patients with type 2 diabetes. This open-label, parallel-group, two-arm, pilot study compared the beta-cell protective effect of adding insulin glargine (GLA) vs. NPH insulin to ongoing metformin.

Material and methods: Overall, 28 insulin-naive type 2 diabetes subjects (mean +/- SD age, 61.5 +/- 6.7 years; diabetes duration, 9.8 +/- 6.5 years; HbA1c, 7.1 +/- 0.5%; BMI, 30.7 +/- 4.3 kg/m(2)) treated with metformin and sulfonylurea were randomized to add once-daily GLA or NPH at bedtime. At baseline and after 3 months, subjects received a standardized breakfast, lunch and dinner, with pre- and postprandial blood sampling to measure plasma IP, total insulin and blood glucose (BG).

Results: Insulin dose after 3 months was comparable in both groups (GLA vs. NPH: 23.6 +/- 13.4 vs. 23.3 +/- 12.7; p = NS ). Both treatments significantly reduced fasting BG levels (GLA: 158 +/- 19 to 121 +/- 23 mg/dl; NPH: 156 +/- 34 to 119 +/- 29 mg/dl; both p < 0.01 vs. baseline). Fasting and postprandial BG levels did not differ between groups. IP levels decreased in both groups (p < 0.05 at all timepoints). Although IP release after breakfast did not differ between treatments, GLA induced a greater reduction in IP release after lunch (p = 0.08) and dinner (p = 0.04). Total plasma insulin levels did not differ between groups.

Conclusions: Adding basal insulin to metformin reduces postprandial beta-cell load. While GLA and NPH had comparable effects at breakfast, GLA reduces beta-cell stress more effectively at dinner, and with a trend at lunch, most probably because of its longer lasting pharmacodynamic profile.

Trial registration: ClinicalTrials.gov NCT00941148.

Figures

Figure 1
Figure 1
Area under the curve (AUC) for 1- and 2-hour postprandial intact proinsulin levels after 3 months of treatment with adding evening insulin glargine vs. NPH insulin to metformin 1000 mg twice daily at breakfast (A), lunch (B), dinner (C) (white: NPH Insulin, black: Insulin Glargine).

References

    1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet. 1998;352:837–853.
    1. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427–2443.
    1. Pfutzner A, Kunt T, Hohberg C, et al. Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes. Diabetes Care. 2004;27:682–687.
    1. Kahn SE. The importance of the beta-cell in the pathogenesis of type 2 diabetes mellitus. Am J Med. 2000;108(Suppl. 6a):2S–8S.
    1. Zethelius B, Lithell H, Hales CN, Berne C. Insulin sensitivity, proinsulin and insulin as predictors of coronary heart disease. A population-based 10-year, follow-up study in 70-year old men using the euglycaemic insulin clamp. Int J Obes Relat Metab Disord. 2005;48:862–867.
    1. Alssema M, Dekker JM, Nijpels G, Stehouwer CD, Bouter LM, Heine RJ. Proinsulin concentration is an independent predictor of all-cause and cardiovascular mortality: an 11-year follow-up of the Hoorn Study. Diabetes Care. 2005;28:860–865.
    1. Forst T, Pfutzner A, Lubben G, et al. Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk–the PIOSTAT Study. Metabolism. 2007;56:491–496.
    1. Dworacka M, Abramczyk M, Winiarska H, Kuczynski S, Borowska M, Szczawinska K. Disproportionately elevated proinsulin levels in type 2 diabetic patients treated with sulfonylurea. Int J Clin Pharmacol Ther. 2006;44:14–21.
    1. Inoguchi T, Umeda F, Kakimoto M, et al. Chronic sulfonylurea treatment and hyperglycemia aggravate disproportionately elevated plasma proinsulin levels in patients with type 2 diabetes. Endocr J. 2000;47:763–770.
    1. Forst T, Hohberg C, Pfutzner A. Cardiovascular effects of disturbed insulin activity in metabolic syndrome and in type 2 diabetic patients. Horm Metab Res. 2009;41:123–131.
    1. Jain SK, Nagi DK, Slavin BM, Lumb PJ, Yudkin JS. Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control. Diabet Med. 1993;10:27–32.
    1. Pfutzner A, Lorra B, Abdollahnia MR, et al. The Switch from Sulfonylurea to Preprandial Short- Acting Insulin Analog Substitution Has an Immediate and Comprehensive beta-Cell Protective Effect in Patients with Type 2 Diabetes Mellitus. Diabetes Technol Ther. 2006;8:375–384.
    1. De Mattia G, Laurenti O, Moretti A. Comparison of glycaemic control in patients with Type 2 diabetes on basal insulin and fixed combination oral antidiabetic treatment: results of a pilot study. Acta Diabetol. 2009;46:67–73.
    1. Wallander M, Bartnik M, Efendic S, et al. Beta cell dysfunction in patients with acute myocardial infarction but without previously known type 2 diabetes: a report from the GAMI study. Int J Obes Relat Metab Disord. 2005;48:2229–2235.
    1. Kirchhoff K, Machicao F, Haupt A, et al. Polymorphisms in the TCF7L2, CDKAL1 and SLC30A8 genes are associated with impaired proinsulin conversion. Int J Obes Relat Metab Disord. 2008;51:597–601.
    1. Fritsche A, Madaus A, Stefan N, et al. Relationships among age, proinsulin conversion, and beta-cell function in nondiabetic humans. Diabetes. 2002;51(Suppl. 1):S234–S239.
    1. Haffner SM, D’Agostino R, Mykkanen L, et al. Proinsulin and insulin concentrations in relation to carotid wall thickness: Insulin Resistance Atherosclerosis Study. Stroke. 1998;29:1498–1503.
    1. Jia EZ, Yang ZJ, Zhu TB, et al. Proinsulin is an independent predictor of the angiographical characteristics of coronary atherosclerosis. Cardiology. 2007;110:106–111.
    1. Yudkin JS, May M, Elwood P, Yarnell JW, Greenwood R, Davey SG. Concentrations of proinsulin like molecules predict coronary heart disease risk independently of insulin: prospective data from the Caerphilly Study. Diabetologia. 2002;45:327–336.
    1. Lindahl B, Dinesen B, Eliasson M, Roder M, Hallmans G, Stegmayr B. High proinsulin levels precede first-ever stroke in a nondiabetic population. Stroke. 2000;31:2936–2941.
    1. Galloway JA, Hooper SA, Spradlin CT, et al. Biosynthetic human proinsulin. Review of chemistry, in vitro and in vivo receptor binding, animal and human pharmacology studies, and clinical trial experience. Diabetes Care. 1992;15:666–692.
    1. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49:2142–2148.
    1. Pfutzner A, Pfutzner AH, Larbig M, Forst T. Role of intact proinsulin in diagnosis and treatment of type 2 diabetes mellitus. Diabetes Technol Ther. 2004;6:405–412.
    1. Pfutzner A, Kann PH, Pfutzner AH, et al. Intact and total proinsulin: new aspects for diagnosis and treatment of type 2 diabetes mellitus and insulin resistance. Clin Lab. 2004;50:567–573.
    1. Haffner SM, Bowsher RR, Mykkanen L, et al. Proinsulin and specific insulin concentration in high- and low-risk populations for NIDDM. Diabetes. 1994;43:1490–1493.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren